Belvedere Trading’s Lifecore Biomedical LFCR Stock Holding History

Belvedere Trading’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-12,900	Closed	-$79.9K	–	837
2023 Q4	$79.9K	Sell	12,900 -6,700	-34%	-$46.5K	﹤0.01%	499
2023 Q3	$148K	Sell	19,600 -25,100	-56%	-$229K	﹤0.01%	264
2023 Q2	$432K	Buy	+44,700	New	+$273K	﹤0.01%	162

Other funds holding LFCR

Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return

LPAM

Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return

GRIM

Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

325 Capital New York $274M AUM 49.96% 1-Year Est. Return

CSC

Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VWA

Visionary Wealth Advisors O'fallon, Illinois $2.26B AUM 19.48% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Belvedere Trading's LFCR Position: Q1 2024 in Review

Belvedere Trading sold out of Lifecore Biomedical (LFCR) in Q1 2024, closing a stake of 194 shares — an estimated $1.2K sold.

Belvedere Trading first reported a position in LFCR in Q1 2023 and held it in 2 quarters. The position peaked at $155K in Q1 2023. 79 funds tracked by Wall St. Rank hold LFCR as of Q1 2024.

Belvedere Trading reported no remaining Lifecore Biomedical position as of Q1 2024 after selling out during the quarter.
Belvedere Trading sold 194 Lifecore Biomedical shares in Q1 2024, an estimated $1.2K.
Belvedere Trading first reported a position in Lifecore Biomedical in Q1 2023 and held it in 2 quarters.
Belvedere Trading's Lifecore Biomedical position peaked at $155K in Q1 2023.
79 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q1 2024.

Based on Belvedere Trading's 13F filing for Q1 2024, filed 9 May 2024.